The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Multiple sclerosis: Side effects of interferon beta therapy and their management
Abstract
Article abstract-Interferon beta (IFNbeta) reduces the relapse rate, disease activity as measured by serial MRI scanning, and disease progression of MS. Therapy with IFNbeta may be associated with a number of adverse reactions. Relatively frequent side effects include flu-like symptoms, transient laboratory abnormalities, menstrual disorders, and increased spasticity. Dermal injection site reactions occur after subcutaneous application of IFNbeta-1b and IFNbeta-1a. Possible side effects of IFNbeta include various autoimmune reactions, capillary leak syndrome, anaphylactic shock, thrombotic-thrombocytopenic purpura, insomnia, headache, alopecia, and depression. We discuss the mechanisms and management of the different side effects of IFNbeta.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,450
The IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.655 · Cited by 2,085
Ebers, G. C. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03334-0 · Cited by 2,073
Paty, D. W., Li, D. K. B., the UBC MS/MRI Study Group, & the IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.662 · Cited by 1,967
Kappos, L. (1998) · The Lancet · doi:10.1016/s0140-6736(98)10039-9 · Cited by 936
The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1995) · Neurology · doi:10.1212/wnl.45.7.1277 · Cited by 916
Cause of death in patients attending multiple sclerosis clinics
Sadovnick, A. D., Eisen, K., Ebers, G. C., & Paty, D. W. (1991) · Neurology · doi:10.1212/wnl.41.8.1193 · Cited by 401
Neuropsychology of multiple sclerosis: A critical review
Rao, S. M. (1986) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/01688638608405173 · Cited by 387
Mood Disorder and Multiple Sclerosis
Joffe, R. T., Lippert, G. P., Gray, T. A., Sawa, G., & Horvath, Z. (1987) · Archives of Neurology · doi:10.1001/archneur.1987.00520160018007 · Cited by 387
Cited by
Quality of life in multiple sclerosis: the impact of depression, fatigue and disability
Amato, M. P., Ponziani, G., Rossi, F., Liedl, C. L., Stefanile, C., & Rossi, L. (2001) · Multiple Sclerosis Journal · doi:10.1177/135245850100700511 · Cited by 506
Hepatotoxicity of Chemotherapy
Floyd, J., Mirza, I., Sachs, B., & Perry, M. C. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.11.002 · Cited by 279
Hadjimichael, O., Vollmer, T., & Oleen-Burkey, M. (2008) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-6-100 · Cited by 240
Honig, A., Kuyper, A. M. G., Schene, A. H., van Melle, J. P., de Jonge, P., Tulner, D. M., Schins, A., Crijns, H. J. G. M., Kuijpers, P. M. J. C., Vossen, H., et al. (2007) · Psychosomatic Medicine · doi:10.1097/psy.0b013e31814b260d · Cited by 167
Zivadinov, R., Zorzon, M., Tommasi, M. A., Nasuelli, D., Bernardi, M., Monti-Bragadin, L., & Cazzato, G. (2003) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(03)00225-9 · Cited by 81
Metadata
- Authors
- Walther, E. U., & Hohlfeld, R.
- Venue
- Neurology
- Published
- 1999-11
- Volume
- 53
- Issue
- 8
- Pages
- 1622-1622
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2038316210
- Cited by
- 304
- References
- 36
- FWCI
- 4.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Multiple sclerosis: Side effects of interferon beta therapy and their management. https://app.cochat.ai/papers/10.1212/wnl.53.8.1622
- The paper
- Walther, E. U., & Hohlfeld, R. (1999). Multiple sclerosis: Side effects of interferon beta therapy and their management. Neurology. https://doi.org/10.1212/wnl.53.8.1622
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.